JPRN-jRCT2031210090已完成1 期
Repeated dose study of NPC-25 in healthy adult male volunteers. - NPC-25-2
Kitamura Motohiro0 个研究点目标入组 48 人开始时间: 2021年5月13日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 < 35age old(—)
- 性别
- Male
入选标准
- •(1) Subjects aged from 20 to 35 years healthy adult Japanese male
- •(2) Subjects with BMI (body mass index:weight (kg) / height (m) 2 ) of 18.5 or more and less than 25.0
- •(3) Subjects whose serum zinc concentration at the time of screening test (within 4 weeks before the start of
- •the clinical trial) is less than 100 microgram / dL
- •(4) Signature of the subjects on the Informed Consent Form
排除标准
- •(1) Drug addicts, alcohol addicts.
- •(2) Subjects with a history of visceral disease or surgery that may affect drug metabolism or excretion.
- •(3) Subjects who can not keep drinking or smoking cessation during hospitalization.
- •(4) Subjects with allergies or hypersensitivity to zinc containing preparations (including supplements).
- •(5) Subjects who have taken zinc containing preparations or zinc containing supplements that are prohibited
- •from being used in combination within 4 weeks before the start of the clinical trial.
- •(6) Subjects who participated in other clinical trials within 12 weeks before the start of the clinical trial.
- •(7) Subjects whose serum copper concentration deviates from the normal standard value range.
- •(8) Subjects who donated 400 mL or more within 12 weeks, 200 mL or more within 4 weeks, and subjects
- •who donated component blood within 2 weeks before the start of the clinical trial.
- •(9) Other patients considered inappropriate by the investigators for inclusion in the study.
研究者
相似试验
已完成
1 期
Repeated dose study of NPC-22SialorrheaJPRN-jRCT2031210169Miyoshi Katsunori16
已完成
1 期
To Evaluate the Safety, Tolerability and Pharmacokinetics of Oral NNZ-2591 in Healthy VolunteersHealthy VolunteersNCT04379869Neuren Pharmaceuticals Limited28
已完成
不适用
PC-SOD NE (Phase I) -Repeated Dose Study in healthy volunteersidiopathic pulmonary fibrosisJPRN-UMIN000008921TT Bio Pharma Co., LTD.8
终止
2 期
Cemdisiran and eculizumab dose-ranging study for paroxysmal nocturnal haemoglobinuriaParoxysmal nocturnal haemoglobinuria (PNH)Haematological DisordersParoxysmal nocturnal haemoglobinuria [Marchiafava-Micheli]ISRCTN31882639niversity of Leeds9
未知
1 期
Repeated administration of DSP-5423P in patients with SchizophreniaSchizophreniaJPRN-jRCT2080222373Dainippon Sumitomo Pharma Co., Ltd.8
